List of Excipients in API ruxolitinib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing ruxolitinib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Incyte Corporation | JAKAFI | ruxolitinib | 50881-005 | CELLULOSE, MICROCRYSTALLINE | 2028-12-12 |
| Incyte Corporation | JAKAFI | ruxolitinib | 50881-005 | HYDROXYPROPYL CELLULOSE | 2028-12-12 |
| Incyte Corporation | JAKAFI | ruxolitinib | 50881-005 | LACTOSE MONOHYDRATE | 2028-12-12 |
| Incyte Corporation | JAKAFI | ruxolitinib | 50881-005 | MAGNESIUM STEARATE | 2028-12-12 |
| Incyte Corporation | JAKAFI | ruxolitinib | 50881-005 | POVIDONE | 2028-12-12 |
| Incyte Corporation | JAKAFI | ruxolitinib | 50881-005 | SILICON DIOXIDE | 2028-12-12 |
| Incyte Corporation | JAKAFI | ruxolitinib | 50881-005 | SODIUM STARCH GLYCOLATE TYPE A POTATO | 2028-12-12 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for ruxolitinib
Excipient focus: CELLULOSE, MICROCRYSTALLINE
ruxolitinib drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-005 |
| >Company | >Ingredient | >NDC |
ruxolitinib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-007 |
| >Company | >Ingredient | >NDC |
Excipient focus: CETYL ALCOHOL
ruxolitinib drug variants containing CETYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-007 |
| >Company | >Ingredient | >NDC |
ruxolitinib drug variants not containing CETYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-005 |
| >Company | >Ingredient | >NDC |
Excipient focus: DIMETHICONE 350
ruxolitinib drug variants containing DIMETHICONE 350
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-007 |
| >Company | >Ingredient | >NDC |
ruxolitinib drug variants not containing DIMETHICONE 350
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-005 |
| >Company | >Ingredient | >NDC |
Excipient focus: EDETATE DISODIUM
ruxolitinib drug variants containing EDETATE DISODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-007 |
| >Company | >Ingredient | >NDC |
ruxolitinib drug variants not containing EDETATE DISODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-005 |
| >Company | >Ingredient | >NDC |
Excipient focus: GLYCERYL STEARATE SE
ruxolitinib drug variants containing GLYCERYL STEARATE SE
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-007 |
| >Company | >Ingredient | >NDC |
ruxolitinib drug variants not containing GLYCERYL STEARATE SE
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-005 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE
ruxolitinib drug variants containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-005 |
| >Company | >Ingredient | >NDC |
ruxolitinib drug variants not containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-007 |
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
ruxolitinib drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-005 |
| >Company | >Ingredient | >NDC |
ruxolitinib drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-007 |
| >Company | >Ingredient | >NDC |
Excipient focus: LIGHT MINERAL OIL
ruxolitinib drug variants containing LIGHT MINERAL OIL
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-007 |
| >Company | >Ingredient | >NDC |
ruxolitinib drug variants not containing LIGHT MINERAL OIL
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-005 |
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
ruxolitinib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-005 |
| >Company | >Ingredient | >NDC |
ruxolitinib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-007 |
| >Company | >Ingredient | >NDC |
Excipient focus: MEDIUM-CHAIN TRIGLYCERIDES
ruxolitinib drug variants containing MEDIUM-CHAIN TRIGLYCERIDES
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-007 |
| >Company | >Ingredient | >NDC |
ruxolitinib drug variants not containing MEDIUM-CHAIN TRIGLYCERIDES
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-005 |
| >Company | >Ingredient | >NDC |
Excipient focus: METHYLPARABEN
ruxolitinib drug variants containing METHYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-007 |
| >Company | >Ingredient | >NDC |
ruxolitinib drug variants not containing METHYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-005 |
| >Company | >Ingredient | >NDC |
Excipient focus: PHENOXYETHANOL
ruxolitinib drug variants containing PHENOXYETHANOL
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-007 |
| >Company | >Ingredient | >NDC |
ruxolitinib drug variants not containing PHENOXYETHANOL
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-005 |
| >Company | >Ingredient | >NDC |
Excipient focus: PHOSPHORIC ACID
ruxolitinib drug variants containing PHOSPHORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-007 |
| >Company | >Ingredient | >NDC |
ruxolitinib drug variants not containing PHOSPHORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-005 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 200
ruxolitinib drug variants containing POLYETHYLENE GLYCOL 200
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-007 |
| >Company | >Ingredient | >NDC |
ruxolitinib drug variants not containing POLYETHYLENE GLYCOL 200
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-005 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYSORBATE 20
ruxolitinib drug variants containing POLYSORBATE 20
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-007 |
| >Company | >Ingredient | >NDC |
ruxolitinib drug variants not containing POLYSORBATE 20
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-005 |
| >Company | >Ingredient | >NDC |
Excipient focus: POVIDONE
ruxolitinib drug variants containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-005 |
| >Company | >Ingredient | >NDC |
ruxolitinib drug variants not containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-007 |
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE GLYCOL
ruxolitinib drug variants containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-007 |
| >Company | >Ingredient | >NDC |
ruxolitinib drug variants not containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-005 |
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLPARABEN
ruxolitinib drug variants containing PROPYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-007 |
| >Company | >Ingredient | >NDC |
ruxolitinib drug variants not containing PROPYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-005 |
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
ruxolitinib drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-005 |
| >Company | >Ingredient | >NDC |
ruxolitinib drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-007 |
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STARCH GLYCOLATE TYPE A POTATO
ruxolitinib drug variants containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-005 |
| >Company | >Ingredient | >NDC |
ruxolitinib drug variants not containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-007 |
| >Company | >Ingredient | >NDC |
Excipient focus: STEARYL ALCOHOL
ruxolitinib drug variants containing STEARYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-007 |
| >Company | >Ingredient | >NDC |
ruxolitinib drug variants not containing STEARYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-005 |
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
ruxolitinib drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-007 |
| >Company | >Ingredient | >NDC |
ruxolitinib drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-005 |
| >Company | >Ingredient | >NDC |
Excipient focus: WHITE PETROLATUM
ruxolitinib drug variants containing WHITE PETROLATUM
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-007 |
| >Company | >Ingredient | >NDC |
ruxolitinib drug variants not containing WHITE PETROLATUM
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-005 |
| >Company | >Ingredient | >NDC |
Excipient focus: XANTHAN GUM
ruxolitinib drug variants containing XANTHAN GUM
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-007 |
| >Company | >Ingredient | >NDC |
ruxolitinib drug variants not containing XANTHAN GUM
| Company | Ingredient | NDC |
|---|---|---|
| Incyte Corporation | ruxolitinib | 50881-005 |
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links